If you experience persistent fatigue, weakness, or other concerning symptoms, medical evaluation is warranted to rule out complications or the need for treatment modification
Introduction New solutions to diabetes control and weight loss have been approved for use
However, patients with chronic kidney disease stage 3 or higher should follow ADA/KDIGO guidelines of approximately 0.8 g/kg/day and have kidney function assessed before significantly increasing protein intake
A notable research effort, known as the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trial, revealed that participants taking Semaglutide GLP-1 achieved an average weight reduction of around 15% of their starting body weight within 68 weeks, unlike those taking a placebo
Pool of Placebo- and Active-Controlled Trials The occurrence of adverse reactions was also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in 9 placebo- and active-controlled trials [see Clinical Studies (14)]